Updated 08:04 GMT, 17 Nov 2026 SPX 7,416.59 -1.92% NDX 27,197.15 -2.67% VIX 22.91 +18.70% GOLD 3,875.30 +0.58% CL 85.14 -0.68% BTC 64,609.30 -0.38%
NAS100 27,197 −2.67% S&P 7,417 −1.92% GOLD $3,875 +0.58% BTC $64,609 −0.38% VIX 22.91 +18.70% latest tape · as of 08:04 UTC
The Screen · Healthcare

Dr. Reddy's Laboratories

DRREDDY.NS · NSE · INR · Market cap $1.08T

PASS · Titan Ethical · score 95.1
1,397.50 INR

Price as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago

Screened 2026-11-13 · the tape above runs as of 08:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price1,397.50 INR at the 13 Nov 2026 close
  • Fair value698.75. Our model only; no analyst estimate to cross-check.
  • Our value readOvervalued vs our fair value, as of 13 Nov 2026
  • Our regime readMarkup, as of 16 Nov 2026
  • Ethical screenPasses, score 95.1 out of 100
  • Last reviewed13 Nov 2026 (4 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: 698.75 INR to 762.64 INR, base estimate 698.75 INR (screen dated 2026-11-13).

Current read
Markup ?
Overvalued · screened 2026-11-13
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical passes the values gate
Price1,397.50 INR
Fair value698.75Our model only; no analyst estimate to cross-check.
Ethical score95.1/100
Value readOvervaluedas of 13 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup1,185.00+17.9% to today ✓Accumulation gives way to Markup first Markup read since July
2026-10-02Read Accumulation1,185.00+17.9% to today ✓Distribution gives way to Accumulation after a 7% slide in 6 weeks
2026-08-24Read Distribution1,275.60+9.6% to today Markup gives way to Distribution
2026-07-02Read Markup1,275.60+9.6% to today ✓First review on file: Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Dr. Reddy's Laboratories holds its Markup at $1,397.50. Consolidating, no directional conviction, held for 11 days.

As held on the ledger · 2026-11-13
PhaseMarkup
Quantitative stateConsolidating, no directional conviction, held for 11 days
Price at the screen$1,397.50
Valuation17.44 trailing · 21.52 forward price to earnings
Values screenPASS · score 95.1
The Workings

Five Screens, Shown in Full

Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 9.49% Below 33% Interest-bearing debt is just 9.5% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 2.97% Below 33% Cash held in interest-bearing accounts and securities is 3.0% of assets, under the one-third limit. Pass
Receivables 0.37% Below 49% Money owed to the company is 0.4% of assets, under the 49% limit. Pass
Revenue purity 0.05% Below 5% Only 0.1% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Clears, in Plain English

Dr. Reddy's Laboratories clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 9%, inside the ~33% line, and almost none of its income is interest, so it passes.

Read as at 2026-11-16. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when DRREDDY.NS's ethical verdict changes

Today DRREDDY.NS passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our model only; no analyst estimate to cross-check.

Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our 698.75 INR fair value estimate, 4.40% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

698.75Conservative698.75Base case762.64Growth case 1,397.50Price

Fair value range in INR, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 100.0% above the base estimate.

Price History & Projections

Where our models see it going: fair-value estimate 698.75 INR, with a range of 698.75 INR to 762.64 INR, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it gives us pause

At 21.5x forward earnings, the price already runs ahead of the business. It trades 100% above our 698.75 INR fair value, so you would be buying at a premium, not a discount.

The fundamentals · plain-English read
Forward P/E21.5xexpensive even after accounting for its growth
Trailing P/E17.4xreasonably valued
EPS, trailing67.93
EPS, forward55.06
Revenue growth+4.4%slow but positive growth
Profit margin0.0%currently unprofitable
Return on equity16.1%a solid return on shareholder capital
FCF yield1.25%
Dividend yield0.61%
Debt to equity0.18minimal debt: a conservative balance sheet
Market cap$1.08T

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

DRREDDY.NS trades on NSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-16 Markup $1,397.50 +1.8% Entry 16

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (39 analysts) rates it hold, with a mean price target of $1332.

2026-11-05 Markup $1,372.30 +12.9% Entry 15

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.9% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (39 analysts) rates it hold, with a mean price target of $1332.

2026-10-25 Markup $1,216.00 +2.6% Entry 14

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (39 analysts) rates it hold, with a mean price target of $1332.

2026-10-11 Markup · changed $1,185.00 +0.0% Entry 13

The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (39 analysts) rates it hold, with a mean price target of $1332.

2026-10-02 Accumulation · changed $1,185.00 -7.1% Entry 12

The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 7.1% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (39 analysts) rates it hold, with a mean price target of $1332.

2026-08-24 Distribution · changed $1,275.60 +0.0% Entry 11

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (39 analysts) rates it hold, with a mean price target of $1332.

2026-07-23 Markup $1,275.60 +0.0% Entry 10

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (39 analysts) rates it hold, with a mean price target of $1332. It reported earnings in this window, a natural checkpoint for the thesis.

2026-07-22 Markup $1,275.60 +0.0% Entry 9

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (39 analysts) rates it hold, with a mean price target of $1332. It reported earnings in this window, a natural checkpoint for the thesis.

2026-07-21 Markup $1,275.60 +0.0% Entry 8

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (39 analysts) rates it hold, with a mean price target of $1332. It reported earnings in this window, a natural checkpoint for the thesis.

2026-07-20 Markup $1,275.60 +0.0% Entry 7

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (39 analysts) rates it hold, with a mean price target of $1332. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · DRREDDY.NS
DateInsiderTitleTypeSharesValue
2025-10-15 Life Insurance Corporation of India Institution- Corporation 17,140,819 ·
2025-09-17 GVP Family Trust Institution- Corporation 96,095,920 ·
2025-09-17 Prasad (G V) Promoter 96,095,920 ·
2025-09-17 VSD Family Trust Institution- Corporation 75,630,620 ·
2025-06-03 Life Insurance Corporation of India Institution- Corporation 60,189,193 ·
2024-06-12 Life Insurance Corporation of India Institution- Corporation 959,088 ·

Public filings, recorded as found. The full tape lives at Insider Intelligence.

The Ledger's Promise

This entry now belongs to the ledger. Whatever DRREDDY.NS does next, these words stay.

Dr. Reddy's Laboratories · DRREDDY.NS · Markup · $1,397.50
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.